Some days before, shares of Insmed Incorporated (NASDAQ:INSM) fell double digits after the company reported data on a 90 patient Phase 2 trial. Insmed Incorporated (NASDAQ:INSM) stock performance was 7.02% in last session and finished the day at $13.41. Traded volume was 1.55million shares in the last session and the average volume of the stock remained 788.23K shares. The beta of the stock remained 0.69. Insmed Incorporated (NASDAQ:INSM) insider ownership is 1.60%.

Citigroup Inc. initiated coverage on shares of Prothena Corp PLC (NASDAQ:PRTA) in a research report released on Wednesday morning,TheFlyOnTheWall.com reports. The firm issued a buy rating on the stock. Prothena Corporation PLC (NASDAQ:PRTA) rose 8.84 percent to $30.55 Thursday on volume of 343,184.00million shares. The intra-day range of the stock was $27.19 to $31.12. Prothena Corporation PLC (NASDAQ:PRTA) has a market capitalization of $669.14million.

La Jolla Pharmaceutical Company (NASDAQ:LJPC) CEO George F. Tidmarsh acquired 8,000 shares of the company’s stock in a transaction that occurred on Monday, April 14th. The stock was purchased at an average cost of $9.53 per share, with a total value of $76,240.00. La Jolla Pharmaceutical Company (NASDAQ:LJPC)’s stock on Apr 17, 2014 reported a increase of 9.63% to the closing price of $10.02. Its fifty two weeks range is $2.75 -$19.50. The total market capitalization recorded $72.72million. The overall volume in the last trading session was 175,679.00million shares. In its share capital, LJPC has 7.26million outstanding shares.

Biota Pharmaceuticals Inc (NASDAQ:BOTA), Phase 2 trial of Laninamivir Octanoate for the treatment of influenza in adults. Inovio Pharmaceuticals: Phase 2 VGX-3100 DNA vaccine delivered by electroporation. Biota Pharmaceuticals Inc (NASDAQ:BOTA), Inovio Pharmaceuticals (INO) and Athersys (ATHX) will all be expecting to report top-line phase 2 data by mid 2014. On Thursday, shares of Biota Pharmaceuticals Inc (NASDAQ:BOTA) advanced 6.01% to close the day at $5.47. Company return on investment (ROI) is -21.20% and its monthly performance is recorded as -11.49%. Biota Pharmaceuticals Inc (NASDAQ:BOTA) quarterly revenue growth is 14.68%.